Pharming Group N.V. announced that the first patient was dosed on March 20, 2025, in a Phase II clinical trial of leniolisib for treating common variable immunodeficiency (CVID) with immune dysregulation, involving approximately 20 patients aged 12 and older. CVID has an estimated global prevalence of 39 cases per million, highlighting the significant need for effective therapies in this larger patient population.